Experiencia de un hospital universitario en el manejo de púrpura trombótico trombocitopénico-microangiopatía trombótica no inmune refractaria o en recaída tratado con rituximab: Report of eight cases / Treatment of thrombotic thrombocytopenic purpura with rituximab
Rev. méd. Chile
; 143(6): 809-811, jun. 2015. tab
Article
in Es
| LILACS
| ID: lil-753523
Responsible library:
CL1.1
ABSTRACT
Thrombotic thrombocytopenic purpura, an immune/non-immune thrombotic microangiopathy (TTP/TMA) is associated with high morbidity and mortality, even with appropriate treatment. In patients refractory to standard treatment with plasmapheresis there is no certainty about the best therapeutic strategy. This report shows our experience in eight refractory patients who survived after treatment with rituximab.
Key words
Full text:
1
Index:
LILACS
Main subject:
Purpura, Thrombotic Thrombocytopenic
/
Rituximab
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Es
Journal:
Rev. méd. Chile
Journal subject:
MEDICINA
Year:
2015
Type:
Article